LYSSIKATOS JOSEPH P (CHIEF SCIENTIFIC OFFICER) received a stock award from ENLIVEN THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/17/2026ACC: 0001967150-26-000004
Officer· CHIEF SCIENTIFIC OFFICER
Since Feb 2026
+131.25K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
131.25K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+18.75K
Price / share
—
Trade value
—
% of position
New position
2/12/2026
0.00→18.75K
Total
Net shares
+18.75K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/12/2026 | A · Award | +18.75K | — | — | New position | 0.00 | 18.75K |
| Total | +18.75K | $0.00 | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
112.50K shares
Shares
+112.50K
Strike price
27.16
Held after
112.50K
Exercisable
—
2/12/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock112.50K shares | 2/12/2026 | A · Award | +112.50K | 27.16 | — | 112.50K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned740.19K
Total
740.19K indirect740.19K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 740.19K | Indirect |
| Total | 740.19K | 740.19K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported